Biosimilars Market Current Tendency and Industry Reasoning up to 2025
Biosimilars are highly
similar, comparable version of biologics, which undergo clinical trials to
demonstrate that they have comparable safety, quality and efficacy to an
approved biologic medicine. When the patent of the original product expires,
biosimilars can be manufactured which are approved officially.
Axiom MRC added an “Biosimilars
Market Report, By Technology
(Monoclonal Antibodies, Recombinant DNA, Chromatography, Nuclear Magnetic
Resonance, Electrophoresis, Mass Spectrometry, Western Blotting and Bioassay),
Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated
Proteins and Peptides), Disease, Type and Geography – Global Market Share,
Trend Analysis & Forecast Up To 2025”
Biologics are more
complex than biosimilars drugs, both in composition and method of manufacture.
Biosimilars will not be exact replicas of an approved biologic medicine but may
instead show high similarity. Furthermore, in the United States, approximately
45%, i.e. 133 million of people have suffered with at-least one chronic
disease. According to National Cancer Institute of America, in 2017 the
national expenditures for cancer care was USD 147.3 billion. Whereas, in 2018,
3.9 million new cases of cancer and over 1.9 million cancer deaths were
estimated in Europe.
Biosimilars Market Outlook
The global biosimilars
market is driven by key factors such as rising incidence of chronic diseases,
the emergence of off-patent biologic products and innovative strategies in
enhanced productivity and clinical trial activities for biosimilars. Furthermore,
these drugs are very cost-effective thus making its demand to increase
significantly.
Biosimilars Market Segmental Overview
Biosimilars Market by
Technology
Monoclonal Antibodies
Technology
Recombinant DNA
Technology
Chromatography
Nuclear Magnetic
Resonance Technology
Electrophoresis
Mass Spectrometry
Western Blotting and
Bioassay.
Biosimilars Market by
Product
Recombinant
Non-Glycosylated Proteins
Recombinant Glycosylated
Proteins And
Peptides.
Biosimilars Market by
Disease
Oncology
Chronic Diseases
Autoimmune Diseases
Blood Disorders
Growth Hormone
Deficiency and
Infectious Diseases.
Biosimilars Market by
Type
In-House Manufacturing
And
Contract Manufacturing.
Biosimilars Market by
Geography
North America
Europe
Asia Pacific and
Rest of the World.
Biosimilars Market Key Players
The key players
operating in the biosimilars market includes Sandoz, Pfizer, Teva
Pahrmaceutical, Biocon, Amgen, Samsung Biologics, Mylan, Dr. Reddy’s
Laboratories, Stada Arzneimittel AG, Genentech (Roche Group), Merck Serono
(Merck Group), Celltrion Healthcare and AbbVie Inc.
About Axiom MRC:
Axiom Market Research
& Consulting™ (also known as Axiom MRC), is a full-service market research
and data analytics firm, driven by a simple aim of providing key market
intelligence to companies to assist them in taking informed business decisions
pertaining to their marketing strategy, investments, new product launches,
market competition, consumer or end users, social media trends etc.
Media Contact:
Ganesh Sai
616 Corporate Way,
Suite 2-4268
Valley Cottage, NY, United
States
Tel: +1(845)875-9786,
+44(0) 20 238697007
Comments
Post a Comment